Sistem Pengembangan Kendali Fuzzy Logic Berbasis Mikrokontroler Keluarga Mcs51 (Petrafuz)

This paper presents a Fuzzy Logic Development Tool called PetraFuz which has been developed at Control System Laboratory, Electrical Engineering Department, Petra Christian University. The system consists of a hardware target based on MCS51 microcontroller and a software support running under PC Windows. The system is targeted for developing fuzzy logic based systems. It supports fuzzy logic design, evaluation, assembly language generator and downloading process to the target hardware to perform on-line fuzzy process. Process action and fuzzy parameters could be transferred to PC monitor via RS-232 serial communication, this on-line process parameters is used for fuzzy tuning, i.e. fuzzy if-then rules and fuzzy membership functions. The PetraFuz tool helps very much for Fuzzy system developments, it could reduce development time significantly. The tool could spur the development of fuzzy systems based on microcontroller systems such as fuzzy control systems, fuzzy information processing, etc

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease that increases significantly cardiovascular morbidity and mortality. It is associated with obesity, insulin resistance, beta-cell dysfunction, and hyperglucagonemia, the combination of which typically leads to hyperglycemia. Incretin-based treatment modalities, and in particular glucagon-like peptide 1 (GLP-1) receptor agonists, are able to successfully counteract several of the underlying pathophysiological abnormalities of T2DM. The pancreatic effects of GLP-1 receptor agonists include glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release in a strictly glucose-dependent manner, increased beta-cell proliferation, and decreased beta-cell apoptosis. GLP-1 receptors are widely expressed throughout human body; thus, GLP-1-based therapies exert pleiotropic and multisystemic effects that extend far beyond pancreatic islets. A large body of experimental and clinical data have suggested a considerable protective role of GLP-1 analogs in the cardiovascular system (decreased blood pressure, improved endothelial and myocardial function, functional recovery of failing and ischemic heart, arterial vasodilatation), kidneys (increased diuresis and natriuresis), gastrointestinal tract (delayed gastric emptying, reduced gastric acid secretion), and central nervous system (appetite suppression, neuroprotective properties). The pharmacologic use of GLP-1 receptor agonists has been shown to reduce bodyweight and systolic blood pressure, and significantly improve glycemic control and lipid profile. Interestingly, weight reduction induced by GLP-1 analogs reflects mainly loss of abdominal visceral fat. The critical issue of whether the emerging positive cardiometabolic effects of GLP-1 analogs can be translated into better clinical outcomes for diabetic patients in terms of long-term hard endpoints, such as cardiovascular morbidity and mortality, remains to be elucidated with prospective, large-scale clinical trials